Physician profile
Matthew Flood
NPI 1881950335
$2,075.64
in general payments reported to CMS, 2019-2025
13 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,333 · 2020: $118 · 2021: $55.50 · 2022: $151 · 2023: $26.42 · 2024: $61.49 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $418.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,304.85 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $208.71 | 2020-2023 | Eylea Hd |
| Apellis Pharmaceuticals, INC. | $143.75 | 2025 | Syfovre |
| Genentech USA, INC. | $106.23 | 2021-2024 | Vabysmo |
| Ocular Therapeutix, INC. | $74.00 | 2022-2025 | Dextenza |
| Amgen INC. | $62.77 | 2025 | Tepezza |
| Astellas Pharma US INC | $59.43 | 2025 | Izervay |
| Alcon Vision LLC | $44.43 | 2019-2024 | Hydrus Microstent |
| Harrow Eye, LLC | $25.57 | 2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $18.72 | 2024 | |
| Allergan, INC. | $11.22 | 2021 | |
| Katena Products, INC. (Dba Corza Medical) | $8.59 | 2019 | |
| Optos, INC. | $7.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Flood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.